Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant-Reference-Cited by-同舟云学术

Use of Uridine Triacetate to Reverse Severe Persistent Myelosuppression Following 5-fluorouracil Exposure in a Patient With a c.557A>G Heterozygous DPYD Variant

Published:2021-09 Issue:3 Volume:20 Page:273-278
ISSN:1533-0028
Container-title:Clinical Colorectal Cancer
language:en
Short-container-title:Clinical Colorectal Cancer

Author:

Leung Michael^ORCID,Rogers Jane E.,Shureiqi Imad^ORCID

Publisher

Elsevier BV

Subject

Gastroenterology,Oncology

Reference38 articles.

1. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study;de Gramont;J Clin Oncol,1997

2. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal canccer;Buroker;J Clin Oncol,1994

3. 5-fluorouracil: mechanisms of action and clinical strategies;Longley;Nat Rev Cancer,2003

4. DPYD and fluorouracil-based chemotherapy: mini review and case report;Wigle;Pharmaceutics,2019

5. Fluorouracil in colorectal cancer–a tale of two drug: implications for biochemical modulation;Sobrero;J Clin Oncol,1997

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review;British Journal of Cancer;2024-06-17

2. Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants;JCO Precision Oncology;2024-05

3. DPYDgenetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: A systematic review;2023-12-11

4. Case report: Uridine triacetate in the management of delayed onset 5-fluorouracil toxicity: A case report and review of literature;Frontiers in Pharmacology;2022-09-07

5. Emerging Strategies in Stimuli-Responsive Prodrug Nanosystems for Cancer Therapy;ACS Nano;2022-09-01